Pharma Deals Review, Vol 2005, No 61 (2005)

Font Size:  Small  Medium  Large

Merck Obtains License from BioXell to Develop TREM-1 Products

Business Review Editor

Abstract


BioXell licensed exclusive worldwide rights to Merck & Co. for the development and commercialization of therapeutic and diagnostic products utilizing BioXell’s triggering receptor expressed on myeloid cells (TREM) technology.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.